The DOI matches its Crossref record; 90 of the 90 references it cites were found in a registry or an index.
Nanoparticle-Mediated Pulmonary Drug Delivery: A Review
Open accessAbstract
Colloidal drug delivery systems have been extensively investigated as drug carriers for the application of different drugs via different routes of administration. Systems, such as solid lipid nanoparticles, polymeric nanoparticles and liposomes, have been investigated for a long time for the treatment of various lung diseases. The pulmonary route, owing to a noninvasive method of drug administration, for both local and systemic delivery of an active pharmaceutical ingredient (API) forms an ideal environment for APIs acting on pulmonary diseases and disorders. Additionally, this route offers many advantages, such as a high surface area with rapid absorption due to high vascularization and circumvention of the first pass effect. Aerosolization or inhalation of colloidal systems is currently being extensively studied and has huge potential for targeted drug delivery in the treatment of various diseases. Furthermore, the surfactant-associated proteins present at the interface enhance the effect of these formulations by decreasing the surface tension and allowing the maximum effect. The most challenging part of developing a colloidal system for nebulization is to maintain the critical physicochemical parameters for successful inhalation. The following review focuses on the current status of different colloidal systems available for the treatment of various lung disorders along with their characterization. Additionally, different in vitro, ex vivo and in vivo cell models developed for the testing of these systems with studies involving cell culture analysis are also discussed.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Solid lipid nanoparticles (SLN) for controlled drug delivery â a review of the state of the art
Müller, R. (2000) · European Journal of Pharmaceutics and Biopharmaceutics · doi:10.1016/s0939-6411(00)00087-4 · Cited by 3,759
Development of Nanoparticles for Antimicrobial Drug Delivery
Zhang, L., Pornpattananangkul, D., Hu, C.-M., & Huang, C.-M. (2010) · Current Medicinal Chemistry · doi:10.2174/092986710790416290 · Cited by 886
The role of lipids in pulmonary surfactant
Veldhuizen, R., Nag, K., Orgeig, S., & Possmayer, F. (1998) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/s0925-4439(98)00061-1 · Cited by 725
Inhaled nanoparticles—A current review
Yang, W., Peters, J. I., & Williams, R. O. (2008) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2008.02.011 · Cited by 666
Wood, A. J. J., & Jobe, A. H. (1993) · New England Journal of Medicine · doi:10.1056/nejm199303253281208 · Cited by 666
Nanoparticles for drug delivery to the lungs
Sung, J. C., Pulliam, B. L., & Edwards, D. A. (2007) · Trends in Biotechnology · doi:10.1016/j.tibtech.2007.09.005 · Cited by 643
Mechanisms of macromolecule absorption by the lungs
Patton, J. S. (1996) · Advanced Drug Delivery Reviews · doi:10.1016/0169-409x(95)00113-l · Cited by 641
Chitosan nanoparticles: Preparation, size evolution and stability
Rampino, A., Borgogna, M., Blasi, P., Bellich, B., & Cesàro, A. (2013) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2013.07.034 · Cited by 622
Nanotoxicology and in vitro studies: The need of the hour
Arora, S., Rajwade, J. M., & Paknikar, K. M. (2012) · Toxicology and Applied Pharmacology · doi:10.1016/j.taap.2011.11.010 · Cited by 537
Furrer, R., Jaspers, R. T., Baggerman, H. L., Bravenboer, N., Lips, P., & de Haan, A. (2013) · BioMed Research International · doi:10.1155/2013/935671 · Cited by 531
Targeted delivery of nanoparticles for the treatment of lung diseases
Azarmi, S., Roa, W. H., & Löbenberg, R. (2008) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2007.11.006 · Cited by 440
AmBisome: liposomal formulation, structure, mechanism of action and pre-clinical experience
Adler-Moore, J., & Proffitt, R. T. (2002) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/49.suppl_1.21 · Cited by 339
BUNJES, H., & UNRUH, T. (2007) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2007.04.013 · Cited by 336
Sakagami, M. (2006) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2006.07.012 · Cited by 331
Characterization of the Calu-3 cell line as a tool to screen pulmonary drug delivery
Foster, K. A., Avery, M. L., Yazdanian, M., & Audus, K. L. (2000) · International Journal of Pharmaceutics · doi:10.1016/s0378-5173(00)00452-x · Cited by 256
Solid lipid nanoparticles for pulmonary delivery of insulin
Liu, J., Gong, T., Fu, H., Wang, C., Wang, X., Chen, Q., Zhang, Q., He, Q., & Zhang, Z. (2008) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2008.01.008 · Cited by 248
The Particle has Landed—Characterizing the Fate of Inhaled Pharmaceuticals
Patton, J. S., Brain, J. D., Davies, L. A., Fiegel, J., Gumbleton, M., Kim, K.-J., Sakagami, M., Vanbever, R., & Ehrhardt, C. (2010) · Journal of Aerosol Medicine and Pulmonary Drug Delivery · doi:10.1089/jamp.2010.0836 · Cited by 238
Phase II studies of nebulised Arikace in CF patients with Pseudomonas aeruginosa infection
Clancy, J. P., Dupont, L., Konstan, M. W., Billings, J., Fustik, S., Goss, C. H., Lymp, J., Minic, P., Quittner, A. L., Rubenstein, R. C., et al. (2013) · Thorax · doi:10.1136/thoraxjnl-2012-202230 · Cited by 222
Pardeike, J., Weber, S., Haber, T., Wagner, J., Zarfl, H. P., Plank, H., & Zimmer, A. (2011) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2011.07.040 · Cited by 216
Deposition of Inhaled Particles in the Lungs
Fernández Tena, A., & Casan Clarà, P. (2012) · Archivos de Bronconeumología (English Edition) · doi:10.1016/j.arbr.2012.02.006 · Cited by 213
Wang, W., Zhu, Xie, Li, Xiao, Li, Liu, Wang, S., & Cui, D. (2012) · International Journal of Nanomedicine · doi:10.2147/ijn.s30428 · Cited by 209
Lipid nanoparticles for the delivery of poorly water-soluble drugs
Bunjes, H. (2010) · Journal of Pharmacy and Pharmacology · doi:10.1111/j.2042-7158.2010.01024.x · Cited by 207
Antitubercular inhaled therapy: opportunities, progress and challenges
Pandey, R., & Khuller, G. K. (2005) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dki027 · Cited by 188
Inhalable nanoparticles, a non-invasive approach to treat lung cancer in a mouse model
Roa, W. H., Azarmi, S., Al-Hallak, M. H. D. K., Finlay, W. H., Magliocco, A. M., & Löbenberg, R. (2011) · Journal of Controlled Release · doi:10.1016/j.jconrel.2010.10.035 · Cited by 181
Ehrhardt, C., & Kim, K. (2007) · Springer eBooks · doi:10.1007/978-0-387-74901-3 · Cited by 181
Characterization of indomethacin-loaded lipid nanoparticles by differential scanning calorimetry
Castelli, F., Puglia, C., Sarpietro, M. G., Rizza, L., & Bonina, F. (2005) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2005.08.011 · Cited by 178
Gill, K. K., Nazzal, S., & Kaddoumi, A. (2011) · European Journal of Pharmaceutics and Biopharmaceutics · doi:10.1016/j.ejpb.2011.04.017 · Cited by 173
Nassimi, M., Schleh, C., Lauenstein, H. D., Hussein, R., Hoymann, H. G., Koch, W., Pohlmann, G., Krug, N., Sewald, K., Rittinghausen, S., et al. (2010) · European Journal of Pharmaceutics and Biopharmaceutics · doi:10.1016/j.ejpb.2010.02.014 · Cited by 173
Self-citationPolymeric nanoparticles for pulmonary protein and DNA delivery
Menon, J. U., Ravikumar, P., Pise, A., Gyawali, D., Hsia, C. C. W., & Nguyen, K. T. (2014) · Acta Biomaterialia · doi:10.1016/j.actbio.2014.01.033 · Cited by 173
Inhalable microparticles containing large payload of anti-tuberculosis drugs
Muttil, P., Kaur, J., Kumar, K., Yadav, A. B., Sharma, R., & Misra, A. (2007) · European Journal of Pharmaceutical Sciences · doi:10.1016/j.ejps.2007.06.006 · Cited by 173
Liposomal Formulations for Inhalation
Cipolla, D. C., Gonda, I., & Chan, H. (2013) · Therapeutic Delivery · doi:10.4155/tde.13.71 · Cited by 166
Forbes, B., Shah, A., Martin, G. P., & Lansley, A. B. (2003) · International Journal of Pharmaceutics · doi:10.1016/s0378-5173(03)00129-7 · Cited by 156
Therapeutic Liposomal Dry Powder Inhalation Aerosols for Targeted Lung Delivery
Willis, L., Hayes, D., & Mansour, H. M. (2012) · Lung · doi:10.1007/s00408-011-9360-x · Cited by 148
Yang, R., Yang, S., Shim, W., Cui, F., Cheng, G., Kim, I., Kim, D., Chung, S., & Shim, C. (2008) · Journal of Pharmaceutical Sciences · doi:10.1002/jps.21487 · Cited by 132
Xu, P., Yin, Q., Shen, J., Chen, L., Yu, H., Zhang, Z., & Li, Y. (2013) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2013.06.053 · Cited by 124
Structural properties of solid lipid based colloidal drug delivery systems
Bunjes, H. (2011) · Current Opinion in Colloid & Interface Science · doi:10.1016/j.cocis.2011.06.007 · Cited by 124
Scherließ, R. (2011) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2011.03.053 · Cited by 123
Pulmonary drug delivery with aerosolizable nanoparticles in an ex vivo lung model
Beck‐Broichsitter, M., Gauss, J., Packhaeuser, C. B., Lahnstein, K., Schmehl, T., Seeger, W., Kissel, T., & Gessler, T. (2008) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2008.09.017 · Cited by 122
Beck‐Broichsitter, M., Ruppert, C., Schmehl, T., Guenther, A., Betz, T., Bakowsky, U., Seeger, W., Kissel, T., & Gessler, T. (2010) · Nanomedicine Nanotechnology Biology and Medicine · doi:10.1016/j.nano.2010.10.007 · Cited by 116
Mussi, S. V., Silva, R. C., Oliveira, M. C., Lucci, C. M., Azevedo, R. B., & Ferreira, L. A. M. (2012) · European Journal of Pharmaceutical Sciences · doi:10.1016/j.ejps.2012.10.025 · Cited by 113
Kumar, S. S. D., Mahadevan, S., Vijayaraghavan, R. K., Mandal, A. B., & MacFarlane, D. R. (2013) · European Journal of Pharmaceutical Sciences · doi:10.1016/j.ejps.2013.08.036 · Cited by 112
Dixon, B., Heath, S.-H. D., Kim, R., Suh, J. H., & Hagen, T. M. (2008) · Antioxidants and Redox Signaling · doi:10.1089/ars.2007.1869 · Cited by 110
Biodistribution of Amikacin Solid Lipid Nanoparticles after Pulmonary Delivery
Varshosaz, J., Ghaffari, S., Mirshojaei, S. F., Jafarian‐Dehkordi, A., Atyabi, F., Kobarfard, F., & Azarmi, S. (2013) · BioMed Research International · doi:10.1155/2013/136859 · Cited by 110
Enhanced rifampicin delivery to alveolar macrophages by solid lipid nanoparticles
Chuan, J., Li, Y., Yang, L., Sun, X., Zhang, Q., Gong, T., & Zhang, Z. (2013) · Journal of Nanoparticle Research · doi:10.1007/s11051-013-1634-1 · Cited by 107
Trivedi, R., Redente, E. F., Thakur, A., Riches, D. W. H., & Kompella, U. B. (2012) · Nanotechnology · doi:10.1088/0957-4484/23/50/505101 · Cited by 100
Hood, E. D., Chorny, M., Greineder, C. F., Alferiev, I. S., Levy, R. J., & Muzykantov, V. R. (2014) · Biomaterials · doi:10.1016/j.biomaterials.2014.01.023 · Cited by 98
Low cytotoxicity of solid lipid nanoparticles inin vitroandex vivolung models
Nassimi, M., Schleh, C., Lauenstein, H.-D., Hussein, R., Lübbers, K., Pohlmann, G., Switalla, S., Sewald, K., Müller, M., Krug, N., et al. (2009) · Inhalation Toxicology · doi:10.1080/08958370903005769 · Cited by 98
Self-citationRüdiger, M., Tölle, A., Meier, W. P., & Rüstow, B. (2004) · American Journal of Physiology-Lung Cellular and Molecular Physiology · doi:10.1152/ajplung.00176.2004 · Cited by 98
Systemic heparin delivery by the pulmonary route using chitosan and glycol chitosan nanoparticles
Trapani, A., Gioia, S. D., Ditaranto, N., Cioffi, N., Goycoolea, F. M., Carbone, A., García-Fuentes, M., Conese, M., & Alonso, M. J. (2013) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2013.02.035 · Cited by 95
Park, C., Li, X., Vogt, F. G., Hayes, D., Zwischenberger, J. B., Park, E., & Mansour, H. M. (2013) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2013.06.047 · Cited by 94
Kleemann, E., Schmehl, T., Gessler, T., Bakowsky, U., Kissel, T., & Seeger, W. (2006) · Pharmaceutical Research · doi:10.1007/pl00022055 · Cited by 87
Nano-antibiotics in chronic lung infection therapy against Pseudomonas aeruginosa
Hadinoto, K., & Cheow, W. S. (2014) · Colloids and Surfaces B Biointerfaces · doi:10.1016/j.colsurfb.2014.02.032 · Cited by 85
Nanomaterials in Drug Delivery, Imaging, and Tissue Engineering
(2013) · Wiley eBooks · doi:10.1002/9781118644591 · Cited by 82
Chimote, G., & Banerjee, R. (2010) · Journal of Biomedical Materials Research Part B Applied Biomaterials · doi:10.1002/jbm.b.31608 · Cited by 79
Lipid-based carriers: manufacturing and applications for pulmonary route
Jaafar‐Maalej, C., Elaïssari, A., & Fessi, H. (2012) · Expert Opinion on Drug Delivery · doi:10.1517/17425247.2012.702751 · Cited by 78
Beck‐Broichsitter, M., Kleimann, P., Gessler, T., Seeger, W., Kissel, T., & Schmehl, T. (2011) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2011.10.012 · Cited by 74
Behr, J., Zimmermann, G., Baumgartner, R., Leuchte, H. H., Neurohr, C., Brand, P., Herpich, C., Sommerer, K., Seitz, J., Menges, G., et al. (2009) · Journal of Aerosol Medicine and Pulmonary Drug Delivery · doi:10.1089/jamp.2008.0714 · Cited by 74
Ability of Antioxidant Liposomes to Prevent Acute and Progressive Pulmonary Injury
Hoesel, L. M., Flierl, M. A., Niederbichler, A. D., Rittirsch, D., McClintock, S. D., Reuben, J. S., Pianko, M. J., Stone, W. L., Yang, H., Smith, M. G., et al. (2008) · Antioxidants and Redox Signaling · doi:10.1089/ars.2007.1878 · Cited by 71
Duret, Wauthoz, N., Sebti, Vanderbist, & Amighi (2012) · International Journal of Nanomedicine · doi:10.2147/ijn.s34091 · Cited by 69
Li, M., Neoh, K. G., Wang, R., Zong, B. Y., Tan, J. Y., & Kang, E. T. (2012) · European Journal of Pharmaceutical Sciences · doi:10.1016/j.ejps.2012.10.008 · Cited by 69
Lipid nanoparticles: recent advances☆
MULLER, R. (2007) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2007.05.002 · Cited by 68
Zhao, Y., Li, X., Lu, C., Xu, Y., Lv, H.-F., Dai, D., Zhang, L., Sun, C., Yang, W. P., Li, X., et al. (2011) · Acta Diabetologica · doi:10.1007/s00592-011-0356-z · Cited by 66
Effect of sildenafil on acrolein-induced airway inflammation and mucus production in rats
Wang, T., Liu, Y., Chen, L., Wang, X., Hu, X.-R., Feng, Y.-L., Liu, D., Xu, D., Duan, Y., Lin, J., et al. (2009) · European Respiratory Journal · doi:10.1183/09031936.00055908 · Cited by 66
Beck‐Broichsitter, M., Ruppert, C., Schmehl, T., Günther, A., & Seeger, W. (2013) · Biochimica et Biophysica Acta (BBA) - Biomembranes · doi:10.1016/j.bbamem.2013.10.016 · Cited by 65
Youn, Y. S., Choi, J. S., Lee, C., Kim, I.-S., Oh, K. T., Lee, Lee, K. C., & Park, E. (2013) · International Journal of Nanomedicine · doi:10.2147/ijn.s48197 · Cited by 63
Composition Influence on Pulmonary Delivery of Rifampicin Liposomes
Manca, M. L., Sinico, C., Maccioni, A. M., Díez-Sales, O., Fadda, A. M., & Manconi, M. (2012) · Pharmaceutics · doi:10.3390/pharmaceutics4040590 · Cited by 62
Cipolla, D. C., Wu, H., Eastman, S. J., Redelmeier, T. E., Gonda, I., & Chan, H. (2013) · Journal of Pharmaceutical Sciences · doi:10.1002/jps.23795 · Cited by 62
Preparation and characterization of nonaarginine-modified chitosan nanoparticles for siRNA delivery
Park, S., Jeong, E. J., Lee, J., Rhim, T., Lee, S. K., & Lee, K. Y. (2012) · Carbohydrate Polymers · doi:10.1016/j.carbpol.2012.08.116 · Cited by 60
Beck‐Broichsitter, M., Schmehl, T., Gessler, T., Seeger, W., & Kissel, T. (2011) · Journal of Controlled Release · doi:10.1016/j.jconrel.2011.09.058 · Cited by 60
Mansour, H. M., Duan, Vogt, Li, & Hayes, D. (2013) · International Journal of Nanomedicine · doi:10.2147/ijn.s48631 · Cited by 59
In-vitroandin-vivoevaluation of ciprofloxacin liposomes for pulmonary administration
Liu, C., Shi, J. C., Dai, Q., Yin, X., Zhang, X., & Zheng, A. (2013) · Drug Development and Industrial Pharmacy · doi:10.3109/03639045.2013.858740 · Cited by 55
Mansour, H. M., Wu, Hayes, D., Zwischenberger, & Kuhn, R. J. (2013) · Drug Design Development and Therapy · doi:10.2147/dddt.s40166 · Cited by 50
Nebulised siRNA encapsulated crosslinked chitosan nanoparticles for pulmonary delivery
Sharma, K., Somavarapu, S., Colombani, A., Govind, N., & Taylor, K. M. G. (2013) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2013.07.024 · Cited by 49
In vitroandex vivotoxicological testing of sildenafil-loaded solid lipid nanoparticles
Paranjpe, M., Neuhaus, V., Finke, J. H., Richter, C., Gothsch, T., Kwade, A., Büttgenbach, S., Braun, A. C., & Müller-Goymann, C. C. (2013) · Inhalation Toxicology · doi:10.3109/08958378.2013.810315 · Cited by 48
Self-citationNanobiotechnological Approaches to Delivery of DNA Vaccine Against Fungal Infection
Ribeiro, A. M., Souza, A. C. O., Amaral, A. C., Vasconcelos, N. ‐., Jerônimo, M. S., Carneiro, F. P., Faccioli, L. H., Felipe, M. S. S., Silva, C. L., & Bocca, A. L. (2013) · Journal of Biomedical Nanotechnology · doi:10.1166/jbn.2013.1491 · Cited by 47
Murata, M., Yonamine, T., Tanaka, S., Tahara, K., Tozuka, Y., & Takeuchi, H. (2013) · Journal of Pharmaceutical Sciences · doi:10.1002/jps.23463 · Cited by 41
Neuhaus, V., Schwarz, K., Klee, A., Seehase, S., Förster, C., Pfennig, O., Jonigk, D. D., Fieguth, H., Koch, W., Warnecke, G., et al. (2013) · PLoS ONE · doi:10.1371/journal.pone.0071728 · Cited by 40
Varshosaz, J., Taymouri, S., & Hamishehkar, H. (2013) · Journal of Applied Polymer Science · doi:10.1002/app.39694 · Cited by 38
Salomon, J. J., Galeron, P., Schulte, N. E., Morow, P. R., Severynse-Stevens, D., Huwer, H., Schneider‐Daum, N., Lehr, C., Hickey, A. J., & Ehrhardt, C. (2013) · Therapeutic Delivery · doi:10.4155/tde.13.62 · Cited by 38
Development and characterisation of freeze-dried liposomes containing two anti-asthma drugs
Elhissi, A. M. A., Islam, A., Arafat, B. T., Taylor, M., & Ahmed, W. (2010) · Micro & Nano Letters · doi:10.1049/mnl.2010.0032 · Cited by 38
LPS and bacterial lung inflammation models
Knapp, S. (2009) · Drug Discovery Today Disease Models · doi:10.1016/j.ddmod.2009.08.003 · Cited by 32
In Vitro Models of the Alveolar Epithelial Barrier
Ehrhardt, C., Laue, M. M., & Kim, K. (2007) · Springer eBooks · doi:10.1007/978-0-387-74901-3_11 · Cited by 30
Chen, H., Zhao, Z., Dong, Zhang, Huang, Zhu, & Zhang (2013) · International Journal of Nanomedicine · doi:10.2147/ijn.s44220 · Cited by 29
Ali, R., Mittal, G., Ali, R., et al. (2013) · Journal of Microencapsulation · doi:10.3109/02652048.2013.764937 · Cited by 18
Srinivasan, A. R., & Shoyele, S. (2012) · AAPS PharmSciTech · doi:10.1208/s12249-012-9913-1 · Cited by 18
Absorption of Calcitonin in Oral and Pulmonary Administration with Polymer-coated Liposomes
Takeuchi, H., & Sugihara, H. (2010) · YAKUGAKU ZASSHI · doi:10.1248/yakushi.130.1135 · Cited by 17
Models for pulmonary hypertension
Marsboom, G., & Janssens, S. P. (2004) · Drug Discovery Today Disease Models · doi:10.1016/j.ddmod.2004.11.026 · Cited by 14
Particulate Pulmonary Delivery Systems Containing Anti-Tuberculosis Agents
Gupta, A., Pandya, S. M., Siddiqi, M. I., Agrawal, A. K., Mohan, M., & Misra, A. (2013) · Critical Reviews in Therapeutic Drug Carrier Systems · doi:10.1615/critrevtherdrugcarriersyst.2013005684 · Cited by 14
Nanoparticle as An Emerging Tool in Pulmonary Drug Delivery System
Patel, P., Soni, T. G., Thakkar, V. T., & Gandhi, T. R. (2013) · Micro and Nanosystems · doi:10.2174/18764029113059990002 · Cited by 12
Nanomaterials for Management of Lung Disorders and Drug Delivery
Menon, J. U., Wadajkar, A. S., Xie, Z., & Nguyen, K. T. (2013) · Wiley eBooks · doi:10.1002/9781118644591.ch5 · Cited by 5
Cited by
Diverse Applications of Nanomedicine
Pelaz, B., Alexiou, C., Alvarez-Puebla, R. A., Alves, F., Andrews, A. M., Ashraf, S., Balogh, L. P., Ballerini, L., Bestetti, A., Brendel, C., et al. (2017) · ACS Nano · doi:10.1021/acsnano.6b06040 · Cited by 1,350
Solid Lipid Nanoparticles and Nanostructured Lipid Carriers: Structure, Preparation and Application
Naseri, N., Valizadeh, H., & Zakeri-Milani, P. (2015) · Advanced Pharmaceutical Bulletin · doi:10.15171/apb.2015.043 · Cited by 1,116
Therapeutic efficacy of nanoparticles and routes of administration
Chenthamara, D., Subramaniam, S., Ramakrishnan, S. G., Krishnaswamy, S., Essa, M. M., Lin, F.-H., & Qoronfleh, M. W. (2019) · Biomaterials Research · doi:10.1186/s40824-019-0166-x · Cited by 1,055
Mohammadi-Samani, S., & Ghasemiyeh, P. (2018) · Research in Pharmaceutical Sciences · doi:10.4103/1735-5362.235156 · Cited by 970
Nanostructured lipid carriers for site-specific drug delivery
Khosa, A., Reddi, S., & Saha, R. N. (2018) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2018.04.055 · Cited by 619
Metadata
- Authors
- Paranjpe, M., & Müller-Goymann, C.
- Venue
- International Journal of Molecular Sciences
- Publisher
- MDPI AG
- Published
- 2014-04-08
- Volume
- 15
- Issue
- 4
- Pages
- 5852-5873
- ISSN
- 1422-0067 (ISSN-L)
- OpenAlex
- W1981251269
- Cited by
- 454
- References
- 90
- FWCI
- 18.42
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.